The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
